Evidence map›Paper›PMID 30278042›Full record

ArticlePloS one2018

Properties of viable lyopreserved amnion are equivalent to viable cryopreserved amnion with the convenience of ambient storage.

Sandeep Dhall, Malathi Sathyamoorthy, Jin-Qiang Kuang, Tyler Hoffman, Matthew Moorman, Anne Lerch, Vimal Jacob, Steven Michael Sinclair, Alla Danilkovitch

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Biological properties and surgical applications of the human amniotic membrane.Frontiers in bioengineering and biotechnology · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sandeep DhallOsiris Therapeutics Inc., Columbia, MD, United States of America.ORCID 0000-0002-6910-1921
Malathi SathyamoorthyOsiris Therapeutics Inc., Columbia, MD, United States of America.
Jin-Qiang KuangOsiris Therapeutics Inc., Columbia, MD, United States of America.
Tyler HoffmanOsiris Therapeutics Inc., Columbia, MD, United States of America.
Matthew MoormanOsiris Therapeutics Inc., Columbia, MD, United States of America.ORCID 0000-0001-8236-9546
Anne LerchOsiris Therapeutics Inc., Columbia, MD, United States of America.
Vimal JacobOsiris Therapeutics Inc., Columbia, MD, United States of America.
Steven Michael SinclairOsiris Therapeutics Inc., Columbia, MD, United States of America.
Alla DanilkovitchOsiris Therapeutics Inc., Columbia, MD, United States of America.
Osiris Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human amniotic membrane (AM) has a long history of clinical use for wound treatment. AM serves as a wound protective barrier maintaining proper moisture. AM is anti-inflammatory, anti-microbial and antifibrotic, and supports angiogenesis, granulation tissue formation and wound re-epithelialization. These properties of AM are attributed to its native extracellular matrix, growth factors, and endogenous cells including mesenchymal stem cells. Advances in tissue preservation have helped to overcome the short shelf life of fresh AM and led to the development of AM products for clinical use. Viable cryopreserved amnion (VCAM), which retains all native components of fresh AM, has shown positive outcomes in clinical trials for wound management. However, cryopreservation requires ultra-low temperature storage and shipment that limits widespread use of VCAM. We have developed a lyopreservation technique to allow for ambient storage of living tissues. Here, we compared the structural, molecular, and functional properties of a viable lyopreserved human amniotic membrane (VLAM) with properties of VCAM using in vitro and in vivo wound models. We found that the structure, growth factors, and cell viability of VLAM is similar to that of VCAM and fresh AM. Both, VCAM and VLAM inhibited TNF-α secretion and upregulated VEGF expression in vitro under conditions designed to mimic inflammation and hypoxia in a wound microenvironment, and resulted in wound closure in a diabetic mouse chronic wound model. Taken together, these data demonstrate that VLAM structural and functional properties are equivalent to VCAM but without the constraints of ultra-low temperature storage.

Indexed as

AmnionAnimalsCell MembraneCell SurvivalCryopreservationFreeze DryingHumansIntercellular Signaling Peptides and ProteinsMiceTemperatureTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AWound HealingIntercellular Signaling Peptides and ProteinsTNF protein, humanTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID30278042
PMCPMC6168127
OpenAlexW2895507809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.